These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 19281600)
21. Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan. Desmeules JA; Oestreicher MK; Piguet V; Allaz AF; Dayer P J Pharmacol Exp Ther; 1999 Feb; 288(2):607-12. PubMed ID: 9918565 [TBL] [Abstract][Full Text] [Related]
22. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Andreassen TN; Eftedal I; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O Eur J Clin Pharmacol; 2012 Jan; 68(1):55-64. PubMed ID: 21735164 [TBL] [Abstract][Full Text] [Related]
23. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Susce MT; Murray-Carmichael E; de Leon J Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1356-8. PubMed ID: 16631290 [TBL] [Abstract][Full Text] [Related]
24. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346 [TBL] [Abstract][Full Text] [Related]
25. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563 [TBL] [Abstract][Full Text] [Related]
26. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. Chan S; Edwards SR; Wyse BD; Smith MT Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932 [TBL] [Abstract][Full Text] [Related]
27. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Kummer O; Hammann F; Moser C; Schaller O; Drewe J; Krähenbühl S Eur J Clin Pharmacol; 2011 Jan; 67(1):63-71. PubMed ID: 20857093 [TBL] [Abstract][Full Text] [Related]
28. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. Stamer UM; Zhang L; Book M; Lehmann LE; Stuber F; Musshoff F PLoS One; 2013; 8(3):e60239. PubMed ID: 23555934 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899 [TBL] [Abstract][Full Text] [Related]
30. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients. Naito T; Tashiro M; Ishida T; Ohnishi K; Kawakami J J Clin Pharmacol; 2013 Aug; 53(8):812-8. PubMed ID: 23733622 [TBL] [Abstract][Full Text] [Related]
31. The effect of single-dose tramadol on oxycodone clearance. Curry SC; Watts DJ; Katz KD; Bikin D; Bukaveckas BL J Emerg Med; 2007 Nov; 33(4):407-11. PubMed ID: 17976797 [TBL] [Abstract][Full Text] [Related]
32. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106 [TBL] [Abstract][Full Text] [Related]
33. The analgesic effect of codeine as compared to imipramine in different human experimental pain models. Enggaard TP; Poulsen L; Arendt-Nielsen L; Hansen SH; Bjørnsdottir I; Gram LF; Sindrup SH Pain; 2001 May; 92(1-2):277-82. PubMed ID: 11323149 [TBL] [Abstract][Full Text] [Related]
34. Determination of adrenergic and imidazoline receptor involvement in augmentation of morphine and oxycodone analgesia by clonidine and BMS182874. Gulati A; Bhalla S; Matwyshyn G; Zhang Z; Andurkar SV Pharmacology; 2009; 83(1):45-58. PubMed ID: 19052482 [TBL] [Abstract][Full Text] [Related]
35. A randomized controlled trial and novel mathematical analysis of the analgesic effect of oxycodone versus paracetamol orodispersible tablets. Martini CH; Proto P; Olofsen E; van Velzen M; Aarts L; Dahan A; Niesters M Eur J Pain; 2015 Mar; 19(3):295-304. PubMed ID: 24947675 [TBL] [Abstract][Full Text] [Related]
36. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124 [TBL] [Abstract][Full Text] [Related]
37. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. Peniston JH; Gould E Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907 [TBL] [Abstract][Full Text] [Related]
38. The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. Cleary J; Mikus G; Somogyi A; Bochner F J Pharmacol Exp Ther; 1994 Dec; 271(3):1528-34. PubMed ID: 7996467 [TBL] [Abstract][Full Text] [Related]
39. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Eckhardt K; Li S; Ammon S; Schänzle G; Mikus G; Eichelbaum M Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456 [TBL] [Abstract][Full Text] [Related]
40. A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Staahl C; Christrup LL; Andersen SD; Arendt-Nielsen L; Drewes AM Pain; 2006 Jul; 123(1-2):28-36. PubMed ID: 16600508 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]